These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 1525610)

  • 1. Intensive immunotherapy with recombinant IL2 after autologous bone marrow transplantation is associated with a high incidence of bacterial infections.
    Blaise D; Stoppa AM; Viens P; Sainty D; Fossat C; Miquel M; Olive D; Bouabdallah R; Gabert J; Baume D
    Bone Marrow Transplant; 1992 Aug; 10(2):193-4. PubMed ID: 1525610
    [No Abstract]   [Full Text] [Related]  

  • 2. Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation.
    Favrot MC; Floret D; Negrier S; Cochat P; Bouffet E; Zhou DC; Franks CR; Bijman T; Brunat-Mentigny M; Philip I
    Bone Marrow Transplant; 1989 Sep; 4(5):499-503. PubMed ID: 2790327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of bacterial contamination of bone marrow grafts.
    Schepers KG; Davis JM; Rowley SD
    Prog Clin Biol Res; 1992; 377():379-84. PubMed ID: 1438434
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravenous interleukin-2 just after high dose BCNU and autologous bone marrow transplantation. Report of a multicentric French pilot study.
    Negrier S; Ranchere JY; Philip I; Merrouche Y; Biron P; Blaise D; Attal M; Rebattu P; Clavel M; Pourreau C
    Bone Marrow Transplant; 1991 Oct; 8(4):259-64. PubMed ID: 1756323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in conjunction with autologous bone marrow transplantation.
    Eckerstein A; Slavin S; Weiss L; Naparstek E
    Bone Marrow Transplant; 1990 Jan; 5 Suppl 1():38. PubMed ID: 2317604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adoptive immunotherapy with interleukin 2 in oncology].
    Favrot M; Bouffet E; Négrier S; Combaret V; Philip I; Philip T
    Bull Cancer; 1990; 77(9):925-31. PubMed ID: 2224165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral tuberculosis following autologous bone marrow transplantation for Hodgkin's disease with interleukin-2 and alpha-interferon immunotherapy.
    Toren A; Ackerstein A; Gazit D; Or R; Raveh D; Kupolovicz U; Engelhard D; Nagler A
    Bone Marrow Transplant; 1996 Jul; 18(1):209-10. PubMed ID: 8832017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevention and treatment of bacterial infections in bone marrow transplantation].
    Sanz Alonso MA; Jarque Ramos I
    Rev Clin Esp; 1995 Oct; 195 Spec No():19-21. PubMed ID: 8948731
    [No Abstract]   [Full Text] [Related]  

  • 9. Induction of cutaneous 'graft-versus-host like' reaction by recombinant IL-2 after autologous bone marrow transplantation.
    Costello R; Blaise D; Jacquemier J; Monges G; Stoppa AM; Viens P; Olive D; Bouabdallah M; Brandely ; Gastaut JA
    Bone Marrow Transplant; 1995 Jul; 16(1):199-200. PubMed ID: 7581125
    [No Abstract]   [Full Text] [Related]  

  • 10. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients.
    Mossad SB; Longworth DL; Goormastic M; Serkey JM; Keys TF; Bolwell BJ
    Bone Marrow Transplant; 1996 Aug; 18(2):265-71. PubMed ID: 8864433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
    Benyunes MC; Higuchi C; York A; Lindgren C; Thompson JA; Buckner CD; Fefer A
    Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of bacterial contamination in bone marrow graft.
    D'Antonio D; Iacone A; Fioritoni G; Dragani A; Betti S; Quaglietta AM; Di Gianfilippo R; Accorsi P; Recchia A; Di Girolamo A
    Haematologica; 1991 Mar; 76 Suppl 1():44-5. PubMed ID: 1864553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K; Margolin K; Champlin R; Forman S
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration.
    Klingemann HG; Eaves CJ; Barnett MJ; Eaves AC; Hogge DE; Nantel SH; Reece E; Shepherd JD; Sutherland HJ; Phillips GL
    Bone Marrow Transplant; 1994 Sep; 14(3):389-96. PubMed ID: 7994260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies.
    Vose JM; Bierman PJ; Kessinger A; Coccia PF; Anderson J; Oldham FB; Epstein C; Armitage JO
    Bone Marrow Transplant; 1991 Feb; 7(2):139-43. PubMed ID: 1675592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-2 after autologous bone marrow transplantation as consolidative immunotherapy against minimal residual disease.
    Bosly A; Brice P; Humblet Y; Doyen C; Faille A; Chatelain B; Franks C; Gisselbrecht C; Symann M
    Nouv Rev Fr Hematol (1978); 1990; 32(1):13-6. PubMed ID: 2349079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacterial contamination of autologous bone marrow: reinfusion of culture-positive grafts does not result in clinical sequelae during the posttransplantation course.
    Schwella N; Rick O; Heuft HG; Miksits K; Zimmermann R; Zingsem J; Eckstein R; Huhn D
    Vox Sang; 1998; 74(2):88-94. PubMed ID: 9501406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: results of a prospective, non-randomized study.
    López-Jiménez J; Pérez-Oteyza J; Munoz A; Parra C; Villalón L; Ramos P; Maldonado M; García-Laraña J; Otheo E; Roldán E; García-Avello A; Odriozola J
    Bone Marrow Transplant; 1997 Mar; 19(5):429-34. PubMed ID: 9052907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of high-dose recombinant interleukin 2 after autologous bone marrow transplantation in patients with neuroblastoma: toxicity, efficacy and survival. A Lyon-Marseille-Curie-east of France Group Study.
    Michon J; Négrier S; Coze C; Mathiot C; Frappaz D; Oskam R; Pacquement H; Quintana E; Bouffet E; Bernard JL
    Prog Clin Biol Res; 1994; 385():293-300. PubMed ID: 7972223
    [No Abstract]   [Full Text] [Related]  

  • 20. Granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjunct to autologous bone marrow transplantation (ABMT) in hematology. Results of the interim analysis of the Schering-Plough/Sandoz International trial and considerations on increased safety in the transplant ward.
    Gorin NC; Fouillard L
    Pathol Biol (Paris); 1992 Nov; 39(9):954-5. PubMed ID: 1538950
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.